Form PRE 14A ENTERA BIO LTD. For: 27 September
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Entera Bio Ltd (ENTX)
Entera Bio Ltd stock price live, this page displays NASDAQ ENTX stock exchange data. View the ENTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Entera Bio Ltd real time stock price chart below.
What Is the Entera Bio Ltd Stock Price Today?
The Entera Bio Ltd stock price today is 2,870.
What Is the Stock Symbol for Entera Bio Ltd?
The stock symbol for Entera Bio Ltd is "ENTX."
What Stock Exchange Does Entera Bio Ltd Trade On?
Entera Bio Ltd is listed and trades on the NASDAQ stock exchange.
Is Entera Bio Ltd a Good Stock to Buy?
Determining whether Entera Bio Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ENTX quote. (ISIN: IL0011429839)
What Is the Entera Bio Ltd Stock Price Today?
The Entera Bio Ltd stock price today is 2,870.
What Is the Stock Symbol for Entera Bio Ltd?
The stock symbol for Entera Bio Ltd is "ENTX."
What Stock Exchange Does Entera Bio Ltd Trade On?
Entera Bio Ltd is listed and trades on the NASDAQ stock exchange.
Is Entera Bio Ltd a Good Stock to Buy?
Determining whether Entera Bio Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ENTX quote. (ISIN: IL0011429839)
2.870
-0.020(-0.69%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.820
2.890
52 wk Range
0.910
4.200
ENTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.8202.890
52 wk Range
0.9104.200
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ENTX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
9.750
Upside
+239.72%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Entera Bio Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Form PRE 14A ENTERA BIO LTD. For: 27 September
- Investing.com
- Entera Bio Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Entera Bio Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 9.750
(+239.72% Upside)
Earnings
Latest Release
Aug 10, 2026
EPS / Forecast
-0,14 / -0,09
Revenue / Forecast
-- / --
Compare ENTX to Peers and Sector
Metrics to compare | ENTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipENTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −28.9x | −2.2x | −0.4x | |
PEG Ratio | 0.75 | 0.04 | 0.00 | |
Price/Book | 67.7x | −1.6x | 2.6x | |
Price / LTM Sales | - | 92.4x | 3.0x | |
Upside (Analyst Target) | 236.2% | 743.7% | 56.4% | |
Fair Value Upside | Unlock | 9.7% | 7.9% | Unlock |
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Entera Bio (ENTX) Stock Price Today?
The Entera Bio stock price today is 2,870 USD.
What Stock Exchange Does Entera Bio Trade On?
Entera Bio is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Entera Bio?
The stock symbol for Entera Bio is "ENTX."
What Is the Entera Bio Market Cap?
As of today, Entera Bio market cap is 496,920M USD.
What Is Entera Bio's Earnings Per Share (TTM)?
The Entera Bio EPS (TTM) is -0,354.
When Is the Next Entera Bio Earnings Date?
Entera Bio will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is ENTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Entera Bio Stock Split?
Entera Bio has split 0 times.
How Many Employees Does Entera Bio Have?
Entera Bio has 21 employees.
What is the current trading status of Entera Bio (ENTX)?
As of Oct 02, 2026, Entera Bio (ENTX) is trading at a price of 2,870 USD, with a previous close of 2,890 USD. The stock has fluctuated within a day range of 2,820 USD to 2,890 USD, while its 52-week range spans from 0,910 USD to 4,200 USD.
What Is Entera Bio (ENTX) Price Target According to Analysts?
The average 12-month price target for Entera Bio is 9,750 USD, with a high estimate of 11 USD and a low estimate of 9 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +239,72% Upside potential.
What Is the ENTX Premarket Price?
ENTX's last pre-market stock price is 2,760 USD. The pre-market share volume is 40,000, and the stock has decreased by -0,130, or -4,500%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.